Richard Goodwin

Awarded PhD from the University of Edinburgh before post doc at University of Glasgow focusing on the development of the newly emerging field of mass spectrometry imaging (MSI). Started working for AstraZeneca in Sweden in 2011 focusing on drug distribution imaging for neuroscience. Recently redeployed to Cambridge UK to lead the in house MS imaging team which supports a wide range of projects in the study of drug efficacy and safety. The group continues to collaborate extensively with international academic collaborators to improve MSI techniques and in developing new MSI technologies.